nodes	percent_of_prediction	percent_of_DWPC	metapath
Epoprostenol—Angiopathy—Betamethasone—psoriatic arthritis	0.00295	0.00295	CcSEcCtD
Epoprostenol—Bradycardia—Prednisone—psoriatic arthritis	0.00289	0.00289	CcSEcCtD
Epoprostenol—Haemoglobin—Prednisone—psoriatic arthritis	0.00285	0.00285	CcSEcCtD
Epoprostenol—Abdominal discomfort—Methotrexate—psoriatic arthritis	0.00284	0.00284	CcSEcCtD
Epoprostenol—Haemorrhage—Prednisone—psoriatic arthritis	0.00284	0.00284	CcSEcCtD
Epoprostenol—Pancytopenia—Methotrexate—psoriatic arthritis	0.00281	0.00281	CcSEcCtD
Epoprostenol—Syncope—Triamcinolone—psoriatic arthritis	0.0028	0.0028	CcSEcCtD
Epoprostenol—Syncope—Methylprednisolone—psoriatic arthritis	0.0028	0.0028	CcSEcCtD
Epoprostenol—Connective tissue disorder—Prednisone—psoriatic arthritis	0.00279	0.00279	CcSEcCtD
Epoprostenol—Anaphylactic shock—Prednisolone—psoriatic arthritis	0.00277	0.00277	CcSEcCtD
Epoprostenol—Oedema—Prednisolone—psoriatic arthritis	0.00277	0.00277	CcSEcCtD
Epoprostenol—Loss of consciousness—Triamcinolone—psoriatic arthritis	0.00275	0.00275	CcSEcCtD
Epoprostenol—Loss of consciousness—Methylprednisolone—psoriatic arthritis	0.00274	0.00274	CcSEcCtD
Epoprostenol—Shock—Prednisolone—psoriatic arthritis	0.00273	0.00273	CcSEcCtD
Epoprostenol—Cough—Triamcinolone—psoriatic arthritis	0.00273	0.00273	CcSEcCtD
Epoprostenol—Tachycardia—Prednisolone—psoriatic arthritis	0.00271	0.00271	CcSEcCtD
Epoprostenol—Hyperhidrosis—Prednisolone—psoriatic arthritis	0.00268	0.00268	CcSEcCtD
Epoprostenol—Myalgia—Triamcinolone—psoriatic arthritis	0.00266	0.00266	CcSEcCtD
Epoprostenol—Pneumonia—Methotrexate—psoriatic arthritis	0.00266	0.00266	CcSEcCtD
Epoprostenol—Arthralgia—Methylprednisolone—psoriatic arthritis	0.00265	0.00265	CcSEcCtD
Epoprostenol—Myalgia—Methylprednisolone—psoriatic arthritis	0.00265	0.00265	CcSEcCtD
Epoprostenol—Anxiety—Methylprednisolone—psoriatic arthritis	0.00264	0.00264	CcSEcCtD
Epoprostenol—Infestation NOS—Methotrexate—psoriatic arthritis	0.00264	0.00264	CcSEcCtD
Epoprostenol—Infestation—Methotrexate—psoriatic arthritis	0.00264	0.00264	CcSEcCtD
Epoprostenol—Unspecified disorder of skin and subcutaneous tissue—Methylprednisolone—psoriatic arthritis	0.00264	0.00264	CcSEcCtD
Epoprostenol—Depression—Methotrexate—psoriatic arthritis	0.00263	0.00263	CcSEcCtD
Epoprostenol—Flushing—Prednisone—psoriatic arthritis	0.00263	0.00263	CcSEcCtD
Epoprostenol—Dry mouth—Triamcinolone—psoriatic arthritis	0.0026	0.0026	CcSEcCtD
Epoprostenol—Angiopathy—Prednisone—psoriatic arthritis	0.00257	0.00257	CcSEcCtD
Epoprostenol—Confusional state—Methylprednisolone—psoriatic arthritis	0.00257	0.00257	CcSEcCtD
Epoprostenol—Oedema—Triamcinolone—psoriatic arthritis	0.00255	0.00255	CcSEcCtD
Epoprostenol—Anaphylactic shock—Triamcinolone—psoriatic arthritis	0.00255	0.00255	CcSEcCtD
Epoprostenol—Anaphylactic shock—Methylprednisolone—psoriatic arthritis	0.00254	0.00254	CcSEcCtD
Epoprostenol—Syncope—Betamethasone—psoriatic arthritis	0.00254	0.00254	CcSEcCtD
Epoprostenol—Syncope—Dexamethasone—psoriatic arthritis	0.00254	0.00254	CcSEcCtD
Epoprostenol—Infection—Triamcinolone—psoriatic arthritis	0.00253	0.00253	CcSEcCtD
Epoprostenol—Sweating—Methotrexate—psoriatic arthritis	0.00253	0.00253	CcSEcCtD
Epoprostenol—Infection—Methylprednisolone—psoriatic arthritis	0.00253	0.00253	CcSEcCtD
Epoprostenol—Haematuria—Methotrexate—psoriatic arthritis	0.00252	0.00252	CcSEcCtD
Epoprostenol—Shock—Triamcinolone—psoriatic arthritis	0.00251	0.00251	CcSEcCtD
Epoprostenol—Insomnia—Prednisolone—psoriatic arthritis	0.00251	0.00251	CcSEcCtD
Epoprostenol—Shock—Methylprednisolone—psoriatic arthritis	0.0025	0.0025	CcSEcCtD
Epoprostenol—Nervous system disorder—Methylprednisolone—psoriatic arthritis	0.0025	0.0025	CcSEcCtD
Epoprostenol—Loss of consciousness—Dexamethasone—psoriatic arthritis	0.00249	0.00249	CcSEcCtD
Epoprostenol—Loss of consciousness—Betamethasone—psoriatic arthritis	0.00249	0.00249	CcSEcCtD
Epoprostenol—Epistaxis—Methotrexate—psoriatic arthritis	0.00249	0.00249	CcSEcCtD
Epoprostenol—Paraesthesia—Prednisolone—psoriatic arthritis	0.00249	0.00249	CcSEcCtD
Epoprostenol—Tachycardia—Triamcinolone—psoriatic arthritis	0.00249	0.00249	CcSEcCtD
Epoprostenol—Mental disorder—Prednisone—psoriatic arthritis	0.00248	0.00248	CcSEcCtD
Epoprostenol—Tachycardia—Methylprednisolone—psoriatic arthritis	0.00248	0.00248	CcSEcCtD
Epoprostenol—Skin disorder—Methylprednisolone—psoriatic arthritis	0.00247	0.00247	CcSEcCtD
Epoprostenol—Hyperhidrosis—Triamcinolone—psoriatic arthritis	0.00247	0.00247	CcSEcCtD
Epoprostenol—Hyperhidrosis—Methylprednisolone—psoriatic arthritis	0.00246	0.00246	CcSEcCtD
Epoprostenol—Myalgia—Betamethasone—psoriatic arthritis	0.00241	0.00241	CcSEcCtD
Epoprostenol—Myalgia—Dexamethasone—psoriatic arthritis	0.00241	0.00241	CcSEcCtD
Epoprostenol—Anxiety—Dexamethasone—psoriatic arthritis	0.00241	0.00241	CcSEcCtD
Epoprostenol—Anxiety—Betamethasone—psoriatic arthritis	0.00241	0.00241	CcSEcCtD
Epoprostenol—Haemoglobin—Methotrexate—psoriatic arthritis	0.00238	0.00238	CcSEcCtD
Epoprostenol—Hypotension—Methylprednisolone—psoriatic arthritis	0.00238	0.00238	CcSEcCtD
Epoprostenol—Pain—Prednisolone—psoriatic arthritis	0.00237	0.00237	CcSEcCtD
Epoprostenol—Haemorrhage—Methotrexate—psoriatic arthritis	0.00237	0.00237	CcSEcCtD
Epoprostenol—Pharyngitis—Methotrexate—psoriatic arthritis	0.00235	0.00235	CcSEcCtD
Epoprostenol—Musculoskeletal discomfort—Triamcinolone—psoriatic arthritis	0.00232	0.00232	CcSEcCtD
Epoprostenol—Musculoskeletal discomfort—Methylprednisolone—psoriatic arthritis	0.00232	0.00232	CcSEcCtD
Epoprostenol—Anaphylactic shock—Dexamethasone—psoriatic arthritis	0.00231	0.00231	CcSEcCtD
Epoprostenol—Anaphylactic shock—Betamethasone—psoriatic arthritis	0.00231	0.00231	CcSEcCtD
Epoprostenol—Oedema—Betamethasone—psoriatic arthritis	0.00231	0.00231	CcSEcCtD
Epoprostenol—Oedema—Dexamethasone—psoriatic arthritis	0.00231	0.00231	CcSEcCtD
Epoprostenol—Insomnia—Triamcinolone—psoriatic arthritis	0.00231	0.00231	CcSEcCtD
Epoprostenol—Insomnia—Methylprednisolone—psoriatic arthritis	0.0023	0.0023	CcSEcCtD
Epoprostenol—Infection—Dexamethasone—psoriatic arthritis	0.0023	0.0023	CcSEcCtD
Epoprostenol—Infection—Betamethasone—psoriatic arthritis	0.0023	0.0023	CcSEcCtD
Epoprostenol—Paraesthesia—Triamcinolone—psoriatic arthritis	0.00229	0.00229	CcSEcCtD
Epoprostenol—Paraesthesia—Methylprednisolone—psoriatic arthritis	0.00228	0.00228	CcSEcCtD
Epoprostenol—Anaemia—Prednisone—psoriatic arthritis	0.00228	0.00228	CcSEcCtD
Epoprostenol—Shock—Dexamethasone—psoriatic arthritis	0.00228	0.00228	CcSEcCtD
Epoprostenol—Shock—Betamethasone—psoriatic arthritis	0.00228	0.00228	CcSEcCtD
Epoprostenol—Dyspnoea—Triamcinolone—psoriatic arthritis	0.00227	0.00227	CcSEcCtD
Epoprostenol—Nervous system disorder—Dexamethasone—psoriatic arthritis	0.00227	0.00227	CcSEcCtD
Epoprostenol—Nervous system disorder—Betamethasone—psoriatic arthritis	0.00227	0.00227	CcSEcCtD
Epoprostenol—Agitation—Prednisone—psoriatic arthritis	0.00227	0.00227	CcSEcCtD
Epoprostenol—Thrombocytopenia—Dexamethasone—psoriatic arthritis	0.00227	0.00227	CcSEcCtD
Epoprostenol—Thrombocytopenia—Betamethasone—psoriatic arthritis	0.00227	0.00227	CcSEcCtD
Epoprostenol—Tachycardia—Dexamethasone—psoriatic arthritis	0.00226	0.00226	CcSEcCtD
Epoprostenol—Tachycardia—Betamethasone—psoriatic arthritis	0.00226	0.00226	CcSEcCtD
Epoprostenol—Dyspepsia—Triamcinolone—psoriatic arthritis	0.00224	0.00224	CcSEcCtD
Epoprostenol—Dyspepsia—Methylprednisolone—psoriatic arthritis	0.00224	0.00224	CcSEcCtD
Epoprostenol—Hyperhidrosis—Dexamethasone—psoriatic arthritis	0.00224	0.00224	CcSEcCtD
Epoprostenol—Hyperhidrosis—Betamethasone—psoriatic arthritis	0.00224	0.00224	CcSEcCtD
Epoprostenol—Syncope—Prednisone—psoriatic arthritis	0.00221	0.00221	CcSEcCtD
Epoprostenol—Anorexia—Betamethasone—psoriatic arthritis	0.00221	0.00221	CcSEcCtD
Epoprostenol—Anorexia—Dexamethasone—psoriatic arthritis	0.00221	0.00221	CcSEcCtD
Epoprostenol—Urticaria—Prednisolone—psoriatic arthritis	0.0022	0.0022	CcSEcCtD
Epoprostenol—Cardiac disorder—Methotrexate—psoriatic arthritis	0.0022	0.0022	CcSEcCtD
Epoprostenol—Fatigue—Triamcinolone—psoriatic arthritis	0.0022	0.0022	CcSEcCtD
Epoprostenol—Fatigue—Methylprednisolone—psoriatic arthritis	0.00219	0.00219	CcSEcCtD
Epoprostenol—Pain—Triamcinolone—psoriatic arthritis	0.00218	0.00218	CcSEcCtD
Epoprostenol—Loss of consciousness—Prednisone—psoriatic arthritis	0.00217	0.00217	CcSEcCtD
Epoprostenol—Hypotension—Betamethasone—psoriatic arthritis	0.00216	0.00216	CcSEcCtD
Epoprostenol—Hypotension—Dexamethasone—psoriatic arthritis	0.00216	0.00216	CcSEcCtD
Epoprostenol—Angiopathy—Methotrexate—psoriatic arthritis	0.00215	0.00215	CcSEcCtD
Epoprostenol—Mediastinal disorder—Methotrexate—psoriatic arthritis	0.00214	0.00214	CcSEcCtD
Epoprostenol—Chills—Methotrexate—psoriatic arthritis	0.00213	0.00213	CcSEcCtD
Epoprostenol—Musculoskeletal discomfort—Dexamethasone—psoriatic arthritis	0.00211	0.00211	CcSEcCtD
Epoprostenol—Musculoskeletal discomfort—Betamethasone—psoriatic arthritis	0.00211	0.00211	CcSEcCtD
Epoprostenol—Myalgia—Prednisone—psoriatic arthritis	0.0021	0.0021	CcSEcCtD
Epoprostenol—Arthralgia—Prednisone—psoriatic arthritis	0.0021	0.0021	CcSEcCtD
Epoprostenol—Anxiety—Prednisone—psoriatic arthritis	0.00209	0.00209	CcSEcCtD
Epoprostenol—Insomnia—Betamethasone—psoriatic arthritis	0.00209	0.00209	CcSEcCtD
Epoprostenol—Insomnia—Dexamethasone—psoriatic arthritis	0.00209	0.00209	CcSEcCtD
Epoprostenol—Unspecified disorder of skin and subcutaneous tissue—Prednisone—psoriatic arthritis	0.00209	0.00209	CcSEcCtD
Epoprostenol—Gastrointestinal pain—Methylprednisolone—psoriatic arthritis	0.00208	0.00208	CcSEcCtD
Epoprostenol—Paraesthesia—Dexamethasone—psoriatic arthritis	0.00208	0.00208	CcSEcCtD
Epoprostenol—Paraesthesia—Betamethasone—psoriatic arthritis	0.00208	0.00208	CcSEcCtD
Epoprostenol—Mental disorder—Methotrexate—psoriatic arthritis	0.00208	0.00208	CcSEcCtD
Epoprostenol—Hypersensitivity—Prednisolone—psoriatic arthritis	0.00204	0.00204	CcSEcCtD
Epoprostenol—Dyspepsia—Dexamethasone—psoriatic arthritis	0.00204	0.00204	CcSEcCtD
Epoprostenol—Dyspepsia—Betamethasone—psoriatic arthritis	0.00204	0.00204	CcSEcCtD
Epoprostenol—Urticaria—Triamcinolone—psoriatic arthritis	0.00203	0.00203	CcSEcCtD
Epoprostenol—Urticaria—Methylprednisolone—psoriatic arthritis	0.00202	0.00202	CcSEcCtD
Epoprostenol—Body temperature increased—Triamcinolone—psoriatic arthritis	0.00202	0.00202	CcSEcCtD
Epoprostenol—Anaphylactic shock—Prednisone—psoriatic arthritis	0.00201	0.00201	CcSEcCtD
Epoprostenol—Oedema—Prednisone—psoriatic arthritis	0.00201	0.00201	CcSEcCtD
Epoprostenol—Abdominal pain—Methylprednisolone—psoriatic arthritis	0.00201	0.00201	CcSEcCtD
Epoprostenol—Decreased appetite—Betamethasone—psoriatic arthritis	0.00201	0.00201	CcSEcCtD
Epoprostenol—Decreased appetite—Dexamethasone—psoriatic arthritis	0.00201	0.00201	CcSEcCtD
Epoprostenol—Infection—Prednisone—psoriatic arthritis	0.002	0.002	CcSEcCtD
Epoprostenol—Gastrointestinal disorder—Betamethasone—psoriatic arthritis	0.002	0.002	CcSEcCtD
Epoprostenol—Gastrointestinal disorder—Dexamethasone—psoriatic arthritis	0.002	0.002	CcSEcCtD
Epoprostenol—Back pain—Methotrexate—psoriatic arthritis	0.002	0.002	CcSEcCtD
Epoprostenol—Fatigue—Dexamethasone—psoriatic arthritis	0.00199	0.00199	CcSEcCtD
Epoprostenol—Fatigue—Betamethasone—psoriatic arthritis	0.00199	0.00199	CcSEcCtD
Epoprostenol—Shock—Prednisone—psoriatic arthritis	0.00198	0.00198	CcSEcCtD
Epoprostenol—Pain—Betamethasone—psoriatic arthritis	0.00198	0.00198	CcSEcCtD
Epoprostenol—Pain—Dexamethasone—psoriatic arthritis	0.00198	0.00198	CcSEcCtD
Epoprostenol—Nervous system disorder—Prednisone—psoriatic arthritis	0.00198	0.00198	CcSEcCtD
Epoprostenol—Tachycardia—Prednisone—psoriatic arthritis	0.00197	0.00197	CcSEcCtD
Epoprostenol—Skin disorder—Prednisone—psoriatic arthritis	0.00196	0.00196	CcSEcCtD
Epoprostenol—Hyperhidrosis—Prednisone—psoriatic arthritis	0.00195	0.00195	CcSEcCtD
Epoprostenol—Anorexia—Prednisone—psoriatic arthritis	0.00192	0.00192	CcSEcCtD
Epoprostenol—Anaemia—Methotrexate—psoriatic arthritis	0.00191	0.00191	CcSEcCtD
Epoprostenol—Gastrointestinal pain—Dexamethasone—psoriatic arthritis	0.00189	0.00189	CcSEcCtD
Epoprostenol—Gastrointestinal pain—Betamethasone—psoriatic arthritis	0.00189	0.00189	CcSEcCtD
Epoprostenol—Hypersensitivity—Triamcinolone—psoriatic arthritis	0.00188	0.00188	CcSEcCtD
Epoprostenol—Hypersensitivity—Methylprednisolone—psoriatic arthritis	0.00187	0.00187	CcSEcCtD
Epoprostenol—Urticaria—Dexamethasone—psoriatic arthritis	0.00184	0.00184	CcSEcCtD
Epoprostenol—Urticaria—Betamethasone—psoriatic arthritis	0.00184	0.00184	CcSEcCtD
Epoprostenol—Musculoskeletal discomfort—Prednisone—psoriatic arthritis	0.00184	0.00184	CcSEcCtD
Epoprostenol—Dizziness—Prednisolone—psoriatic arthritis	0.00183	0.00183	CcSEcCtD
Epoprostenol—Asthenia—Triamcinolone—psoriatic arthritis	0.00183	0.00183	CcSEcCtD
Epoprostenol—Abdominal pain—Betamethasone—psoriatic arthritis	0.00183	0.00183	CcSEcCtD
Epoprostenol—Body temperature increased—Dexamethasone—psoriatic arthritis	0.00183	0.00183	CcSEcCtD
Epoprostenol—Abdominal pain—Dexamethasone—psoriatic arthritis	0.00183	0.00183	CcSEcCtD
Epoprostenol—Body temperature increased—Betamethasone—psoriatic arthritis	0.00183	0.00183	CcSEcCtD
Epoprostenol—Asthenia—Methylprednisolone—psoriatic arthritis	0.00183	0.00183	CcSEcCtD
Epoprostenol—Insomnia—Prednisone—psoriatic arthritis	0.00182	0.00182	CcSEcCtD
Epoprostenol—Paraesthesia—Prednisone—psoriatic arthritis	0.00181	0.00181	CcSEcCtD
Epoprostenol—Pruritus—Triamcinolone—psoriatic arthritis	0.0018	0.0018	CcSEcCtD
Epoprostenol—Cough—Methotrexate—psoriatic arthritis	0.0018	0.0018	CcSEcCtD
Epoprostenol—Pruritus—Methylprednisolone—psoriatic arthritis	0.0018	0.0018	CcSEcCtD
Epoprostenol—Dyspepsia—Prednisone—psoriatic arthritis	0.00177	0.00177	CcSEcCtD
Epoprostenol—Arthralgia—Methotrexate—psoriatic arthritis	0.00176	0.00176	CcSEcCtD
Epoprostenol—Chest pain—Methotrexate—psoriatic arthritis	0.00176	0.00176	CcSEcCtD
Epoprostenol—Myalgia—Methotrexate—psoriatic arthritis	0.00176	0.00176	CcSEcCtD
Epoprostenol—Decreased appetite—Prednisone—psoriatic arthritis	0.00175	0.00175	CcSEcCtD
Epoprostenol—Rash—Prednisolone—psoriatic arthritis	0.00175	0.00175	CcSEcCtD
Epoprostenol—Dermatitis—Prednisolone—psoriatic arthritis	0.00175	0.00175	CcSEcCtD
Epoprostenol—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—psoriatic arthritis	0.00174	0.00174	CcSEcCtD
Epoprostenol—Diarrhoea—Methylprednisolone—psoriatic arthritis	0.00174	0.00174	CcSEcCtD
Epoprostenol—Fatigue—Prednisone—psoriatic arthritis	0.00174	0.00174	CcSEcCtD
Epoprostenol—Headache—Prednisolone—psoriatic arthritis	0.00174	0.00174	CcSEcCtD
Epoprostenol—Constipation—Prednisone—psoriatic arthritis	0.00172	0.00172	CcSEcCtD
Epoprostenol—Confusional state—Methotrexate—psoriatic arthritis	0.0017	0.0017	CcSEcCtD
Epoprostenol—Dizziness—Triamcinolone—psoriatic arthritis	0.00169	0.00169	CcSEcCtD
Epoprostenol—Anaphylactic shock—Methotrexate—psoriatic arthritis	0.00168	0.00168	CcSEcCtD
Epoprostenol—Dizziness—Methylprednisolone—psoriatic arthritis	0.00168	0.00168	CcSEcCtD
Epoprostenol—Infection—Methotrexate—psoriatic arthritis	0.00167	0.00167	CcSEcCtD
Epoprostenol—Asthenia—Dexamethasone—psoriatic arthritis	0.00166	0.00166	CcSEcCtD
Epoprostenol—Asthenia—Betamethasone—psoriatic arthritis	0.00166	0.00166	CcSEcCtD
Epoprostenol—Nervous system disorder—Methotrexate—psoriatic arthritis	0.00165	0.00165	CcSEcCtD
Epoprostenol—Thrombocytopenia—Methotrexate—psoriatic arthritis	0.00165	0.00165	CcSEcCtD
Epoprostenol—Gastrointestinal pain—Prednisone—psoriatic arthritis	0.00165	0.00165	CcSEcCtD
Epoprostenol—Nausea—Prednisolone—psoriatic arthritis	0.00165	0.00165	CcSEcCtD
Epoprostenol—Pruritus—Dexamethasone—psoriatic arthritis	0.00164	0.00164	CcSEcCtD
Epoprostenol—Pruritus—Betamethasone—psoriatic arthritis	0.00164	0.00164	CcSEcCtD
Epoprostenol—Skin disorder—Methotrexate—psoriatic arthritis	0.00164	0.00164	CcSEcCtD
Epoprostenol—Hyperhidrosis—Methotrexate—psoriatic arthritis	0.00163	0.00163	CcSEcCtD
Epoprostenol—Vomiting—Triamcinolone—psoriatic arthritis	0.00162	0.00162	CcSEcCtD
Epoprostenol—Vomiting—Methylprednisolone—psoriatic arthritis	0.00162	0.00162	CcSEcCtD
Epoprostenol—Rash—Triamcinolone—psoriatic arthritis	0.00161	0.00161	CcSEcCtD
Epoprostenol—Dermatitis—Triamcinolone—psoriatic arthritis	0.00161	0.00161	CcSEcCtD
Epoprostenol—Anorexia—Methotrexate—psoriatic arthritis	0.00161	0.00161	CcSEcCtD
Epoprostenol—Rash—Methylprednisolone—psoriatic arthritis	0.0016	0.0016	CcSEcCtD
Epoprostenol—Dermatitis—Methylprednisolone—psoriatic arthritis	0.0016	0.0016	CcSEcCtD
Epoprostenol—Urticaria—Prednisone—psoriatic arthritis	0.0016	0.0016	CcSEcCtD
Epoprostenol—Headache—Triamcinolone—psoriatic arthritis	0.0016	0.0016	CcSEcCtD
Epoprostenol—Headache—Methylprednisolone—psoriatic arthritis	0.00159	0.00159	CcSEcCtD
Epoprostenol—Abdominal pain—Prednisone—psoriatic arthritis	0.00159	0.00159	CcSEcCtD
Epoprostenol—Body temperature increased—Prednisone—psoriatic arthritis	0.00159	0.00159	CcSEcCtD
Epoprostenol—Diarrhoea—Dexamethasone—psoriatic arthritis	0.00158	0.00158	CcSEcCtD
Epoprostenol—Diarrhoea—Betamethasone—psoriatic arthritis	0.00158	0.00158	CcSEcCtD
Epoprostenol—Hypotension—Methotrexate—psoriatic arthritis	0.00157	0.00157	CcSEcCtD
Epoprostenol—Musculoskeletal discomfort—Methotrexate—psoriatic arthritis	0.00153	0.00153	CcSEcCtD
Epoprostenol—Dizziness—Betamethasone—psoriatic arthritis	0.00153	0.00153	CcSEcCtD
Epoprostenol—Dizziness—Dexamethasone—psoriatic arthritis	0.00153	0.00153	CcSEcCtD
Epoprostenol—Insomnia—Methotrexate—psoriatic arthritis	0.00152	0.00152	CcSEcCtD
Epoprostenol—Nausea—Triamcinolone—psoriatic arthritis	0.00151	0.00151	CcSEcCtD
Epoprostenol—Paraesthesia—Methotrexate—psoriatic arthritis	0.00151	0.00151	CcSEcCtD
Epoprostenol—Nausea—Methylprednisolone—psoriatic arthritis	0.00151	0.00151	CcSEcCtD
Epoprostenol—Dyspnoea—Methotrexate—psoriatic arthritis	0.0015	0.0015	CcSEcCtD
Epoprostenol—Somnolence—Methotrexate—psoriatic arthritis	0.0015	0.0015	CcSEcCtD
Epoprostenol—Hypersensitivity—Prednisone—psoriatic arthritis	0.00148	0.00148	CcSEcCtD
Epoprostenol—Dyspepsia—Methotrexate—psoriatic arthritis	0.00148	0.00148	CcSEcCtD
Epoprostenol—Vomiting—Betamethasone—psoriatic arthritis	0.00147	0.00147	CcSEcCtD
Epoprostenol—Vomiting—Dexamethasone—psoriatic arthritis	0.00147	0.00147	CcSEcCtD
Epoprostenol—Decreased appetite—Methotrexate—psoriatic arthritis	0.00146	0.00146	CcSEcCtD
Epoprostenol—Rash—Betamethasone—psoriatic arthritis	0.00146	0.00146	CcSEcCtD
Epoprostenol—Rash—Dexamethasone—psoriatic arthritis	0.00146	0.00146	CcSEcCtD
Epoprostenol—Dermatitis—Betamethasone—psoriatic arthritis	0.00146	0.00146	CcSEcCtD
Epoprostenol—Dermatitis—Dexamethasone—psoriatic arthritis	0.00146	0.00146	CcSEcCtD
Epoprostenol—Gastrointestinal disorder—Methotrexate—psoriatic arthritis	0.00145	0.00145	CcSEcCtD
Epoprostenol—Fatigue—Methotrexate—psoriatic arthritis	0.00145	0.00145	CcSEcCtD
Epoprostenol—Headache—Betamethasone—psoriatic arthritis	0.00145	0.00145	CcSEcCtD
Epoprostenol—Headache—Dexamethasone—psoriatic arthritis	0.00145	0.00145	CcSEcCtD
Epoprostenol—Asthenia—Prednisone—psoriatic arthritis	0.00145	0.00145	CcSEcCtD
Epoprostenol—Pain—Methotrexate—psoriatic arthritis	0.00144	0.00144	CcSEcCtD
Epoprostenol—Pruritus—Prednisone—psoriatic arthritis	0.00143	0.00143	CcSEcCtD
Epoprostenol—Diarrhoea—Prednisone—psoriatic arthritis	0.00138	0.00138	CcSEcCtD
Epoprostenol—Gastrointestinal pain—Methotrexate—psoriatic arthritis	0.00138	0.00138	CcSEcCtD
Epoprostenol—Nausea—Dexamethasone—psoriatic arthritis	0.00137	0.00137	CcSEcCtD
Epoprostenol—Nausea—Betamethasone—psoriatic arthritis	0.00137	0.00137	CcSEcCtD
Epoprostenol—Urticaria—Methotrexate—psoriatic arthritis	0.00134	0.00134	CcSEcCtD
Epoprostenol—Dizziness—Prednisone—psoriatic arthritis	0.00133	0.00133	CcSEcCtD
Epoprostenol—Abdominal pain—Methotrexate—psoriatic arthritis	0.00133	0.00133	CcSEcCtD
Epoprostenol—Body temperature increased—Methotrexate—psoriatic arthritis	0.00133	0.00133	CcSEcCtD
Epoprostenol—Vomiting—Prednisone—psoriatic arthritis	0.00128	0.00128	CcSEcCtD
Epoprostenol—Rash—Prednisone—psoriatic arthritis	0.00127	0.00127	CcSEcCtD
Epoprostenol—Dermatitis—Prednisone—psoriatic arthritis	0.00127	0.00127	CcSEcCtD
Epoprostenol—Headache—Prednisone—psoriatic arthritis	0.00126	0.00126	CcSEcCtD
Epoprostenol—Hypersensitivity—Methotrexate—psoriatic arthritis	0.00124	0.00124	CcSEcCtD
Epoprostenol—Asthenia—Methotrexate—psoriatic arthritis	0.00121	0.00121	CcSEcCtD
Epoprostenol—Nausea—Prednisone—psoriatic arthritis	0.0012	0.0012	CcSEcCtD
Epoprostenol—Pruritus—Methotrexate—psoriatic arthritis	0.00119	0.00119	CcSEcCtD
Epoprostenol—Diarrhoea—Methotrexate—psoriatic arthritis	0.00115	0.00115	CcSEcCtD
Epoprostenol—Dizziness—Methotrexate—psoriatic arthritis	0.00111	0.00111	CcSEcCtD
Epoprostenol—Vomiting—Methotrexate—psoriatic arthritis	0.00107	0.00107	CcSEcCtD
Epoprostenol—Rash—Methotrexate—psoriatic arthritis	0.00106	0.00106	CcSEcCtD
Epoprostenol—Dermatitis—Methotrexate—psoriatic arthritis	0.00106	0.00106	CcSEcCtD
Epoprostenol—Headache—Methotrexate—psoriatic arthritis	0.00105	0.00105	CcSEcCtD
Epoprostenol—Nausea—Methotrexate—psoriatic arthritis	0.001	0.001	CcSEcCtD
